Piramal Pharma Limited has released the audio recording of its conference call regarding the unaudited financial results for the quarter ended June 30, 2026 (Q1FY27). The call, held on July 30, 2026, covered both standalone and consolidated performance metrics for the period. Investors and stakeholders can access the recording directly through the company’s official website at https://www.piramalpharma.com/financial-reports .

The disclosure was made in continuation of a letter dated July 20, 2026, and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Maneesh Sharma, Company Secretary & Compliance Officer of Piramal Pharma Limited, signed the communication notifying the exchanges.

Disclosure Details

The company notified both BSE Limited and the National Stock Exchange of India Limited regarding the availability of the recording. The filing confirms that the audio file is now public record for stakeholder review.

Regulatory Compliance

The release of the conference call recording is a standard compliance requirement under Indian securities regulations. It ensures transparency and provides equal access to information for all shareholders following the announcement of quarterly financial results. No specific financial figures were detailed in this particular notification, as it serves solely to direct investors to the audio archive.

Piramal Pharma has reaffirmed its ambition to achieve a 25% EBITDA margin across all its businesses by FY30, as stated during its latest earnings conference call. The management's reiteration of this target signals a continued strategic focus on sustained profitability improvement across the company's diversified pharmaceutical portfolio.

EBITDA Margin Target Reaffirmed

During the concall, Piramal Pharma's management reiterated the company's long-term margin objective, setting a clear benchmark for operational performance. The target of 25% EBITDA margin applies uniformly across all business segments, reflecting a comprehensive approach to profitability enhancement.

Strategic Focus on Long-Term Profitability

The reaffirmation of the FY30 EBITDA margin target during the concall highlights the company's commitment to its stated financial roadmap. By setting a uniform margin goal across all business lines, Piramal Pharma underscores the breadth of its operational improvement agenda. The company's management has consistently communicated this objective as a central pillar of its long-term strategy.